Hematology society to develop guidelines on managing sickle cell disease | CDC: Placental, fetal tissue can help determine Zika infection in newborns | Canada responds to shortage of yellow fever vaccine
ADVERTISEMENT
June 23, 2017
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
SIGN UP ⋅   FORWARD
Top Story
Hematology society to develop guidelines on managing sickle cell disease
The American Society of Hematology is working on clinical practice guidelines for the management of sickle cell disease. Five panels will consider topics including blood transfusion therapy and stem cell transplantation, and publication is expected in 2019.
Rare Disease Report (6/19) 
LinkedIn Twitter Facebook Google+ Email
Science & Health
CDC: Placental, fetal tissue can help determine Zika infection in newborns
CDC researchers tested the placental and fetal tissue of newborns for Zika virus infection and found that only 1 in 10 infants at risk from Zika was infected, and infection did not always result in birth defects. The findings were published in the agency's Morbidity and Mortality Weekly Report.
HealthDay News (6/22) 
LinkedIn Twitter Facebook Google+ Email
Canada responds to shortage of yellow fever vaccine
Yellow fever vaccine in Canada is in short supply, and provincial health centers are splitting some doses among multiple patients. Full doses are being prioritized for certain populations, including travelers to nations where the virus is spreading.
Global News Online (Toronto)/The Canadian Press (6/20),  CBC News (Canada) (6/19) 
LinkedIn Twitter Facebook Google+ Email
Emerging Trends
Viruses genetically modified to battle antibiotic-resistant bacteria
Viruses that have been genetically modified using the CRISPR-Cas9 gene-editing system have shown promise in defeating antibiotic-resistant bacteria, a presentation at CRISPR 2017 suggests. Several companies are studying bacteriophages and may be ready to start clinical trials next year.
Nature (free content) (6/21) 
LinkedIn Twitter Facebook Google+ Email
Industry News & Practice
APC, Glenmark sign deal for cell-based anticancer drug
Glenmark Pharmaceuticals gained an exclusive license to APC Therapeutics' antigen-presenting, cell technology-based anticancer compound, which has the potential to be used either as monotherapy or in combination with approved drugs. Under the terms of the deal, Glenmark will handle all clinical development and regulatory and commercialization activities.
Genetic Engineering & Biotechnology News (6/21) 
LinkedIn Twitter Facebook Google+ Email
Malaria research project to receive $9.3M NIH grant
The University of Washington's Malaria Evolution in South Asia initiative will be the recipient of a $9.3 million grant from the NIH to continue research in the fight against drug-resistant malaria, particularly in India. "By getting a clearer picture of malaria in India, we're 'closing the gap' on how this complex parasite behaves globally," said Pradipsinh Rathod, director of NIH International Center of Excellence for Malaria Research for South Asia.
GeekWire (6/20) 
LinkedIn Twitter Facebook Google+ Email
Biotech firm's IPO aims to raise funds for thrombocytopenia lead candidate
Dova Pharmaceuticals is ready for its initial public offering of approximately 4.1 million shares of common stock to fund development of its lead product candidate, avatrombopag, a platelet production stimulant for the treatment of thrombocytopenia. Dova intends to submit a US marketing application next quarter with the FDA.
Seeking Alpha (free registration) (6/21) 
LinkedIn Twitter Facebook Google+ Email
Government & Regulatory
Amgen seeks expanded indication for Xgeva
The FDA accepted Amgen's supplemental application for Xgeva, or denosumab, which is approved to prevent fractures in patients with solid-tumor bone metastases. Amgen seeks to expand its use to include patients with multiple myeloma.
Pacific Coast Business Times (Santa Barbara, Calif.) (6/19) 
LinkedIn Twitter Facebook Google+ Email
Roche's user-friendly version of blood cancer drug Rituxan gains FDA approval
A new formulation of Roche Holding's blockbuster cancer drug Rituxan called Rituxan Hycela can now be given as a subcutaneous injection within a five- to seven-minute period, unlike previous versions of the drug, which require infusion. Rituxan Hycela was approved for the treatment of follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and will be available to US patients in one to two weeks, according to Roche.
Reuters (6/22) 
LinkedIn Twitter Facebook Google+ Email
Association News
AABB announces slate of nominees for 2017-18 Board of Directors
AABB posted biographies and additional information for candidates for open officer and at-large director positions for the 2017-18 AABB Board of Directors. Nominees include Michael Murphy, M.D., FRCP, FRCPath, FFPath, for president-elect; Dana Devine, Ph.D., for vice president; and Dan Waxman, M.D., for secretary. The candidates for these and open at-large director positions were recommended by the AABB Nominating Committee. Members may also submit nominations through the petition process, as specified in AABB's bylaws, by Aug. 11, 2017.
LinkedIn Twitter Facebook Google+ Email
 
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
JOBS
powered by
BLOOD BANK SUPERVISOR
SOUTH NASSAU COMMUNITIES HOSPITAL - Oceanside, NY
  
  
Anyone can hold the helm when the sea is calm.
Publilius Syrus,
writer
LinkedIn Twitter Facebook Google+ Email
  
  
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information